---
title: "Exelixis’s Strategic Oncology Expansion and Pipeline Innovations Justify Buy Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/269384656.md"
description: "William Blair analyst Andy Hsieh maintains a Buy rating on Exelixis (EXEL) stock, citing the company's strategic oncology expansion and pipeline innovations. Exelixis aims to enhance its oncology presence through its Cabometyx franchise and new assets like zanzalintinib. The company is expanding treatment capabilities for various cancers and developing new programs, including antibody-drug-conjugates and a SSTR2 agonist. These initiatives are expected to offset Cabometyx's patent expiration and support long-term growth. Hsieh has a 14.5% average return and a 47.17% success rate on stock recommendations."
datetime: "2025-12-11T13:05:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269384656.md)
  - [en](https://longbridge.com/en/news/269384656.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269384656.md)
---

# Exelixis’s Strategic Oncology Expansion and Pipeline Innovations Justify Buy Rating

William Blair analyst Andy Hsieh has reiterated their bullish stance on EXEL stock, giving a Buy rating today.

### TipRanks Cyber Monday Sale

-   Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
-   Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Andy Hsieh has given his Buy rating due to a combination of factors including Exelixis’s strategic plans to become a leading force in oncology. The company’s management has outlined an ambitious roadmap to expand its reach in the oncology sector, leveraging its successful Cabometyx franchise and introducing new pipeline assets like zanzalintinib to drive future revenue growth.  
Furthermore, Exelixis’s efforts to broaden its treatment capabilities to address a wider range of cancers, such as thoracic, head and neck, and gynecologic cancers, are expected to significantly increase the number of patients they can serve. The development of promising programs, including four antibody-drug-conjugate initiatives and a new SSTR2 agonist small molecule, positions Exelixis to strengthen its presence in the neuroendocrine tumors market. These strategic initiatives are anticipated to help the company navigate the upcoming patent expiration of Cabometyx, supporting long-term growth and justifying the Buy rating.

Hsieh covers the Healthcare sector, focusing on stocks such as Exelixis, Terns Pharmaceuticals, and Corbus Pharmaceuticals. According to TipRanks, Hsieh has an average return of 14.5% and a 47.17% success rate on recommended stocks.

### Related Stocks

- [EXEL.US](https://longbridge.com/en/quote/EXEL.US.md)

## Related News & Research

- [Ameritas Advisory Services LLC Purchases Shares of 34,270 Exelixis, Inc. $EXEL](https://longbridge.com/en/news/286523415.md)
- [Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K. | SOPH Stock News](https://longbridge.com/en/news/286227729.md)
- [Combined Canada Introduces New Cancer Care Insurance Product to Help Canadians Manage the Financial Impact of Cancer](https://longbridge.com/en/news/286300622.md)
- [13:19 ETCancerCheck and Evexia Partner to Make Early, Accurate Cancer Detection a Reality](https://longbridge.com/en/news/286448727.md)
- [RenovoRx Q1 revenue rises as number of active cancer centers increase](https://longbridge.com/en/news/286462396.md)